Updated:
Orna Therapeutics
Orna Therapeutics is leaving linear thinking behind to create fully engineered circular RNA (oRNA) therapeutics – an entirely new class of RNA medicines.
Orna Therapeutics
Orna Therapeutics is leaving linear thinking behind to create fully engineered circular RNA (oRNA) therapeutics – an entirely new class of RNA medicines.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Principals
Joe
Chief Scientific Officer
Hope
General Counsel
Ciaran
Chief Operating Officer
Teresa Lipcsey
Chief Financial Officer
Frank Neumann
Chief Medical Officer
Siva
Chief Technology Officer
Brian
Chief Business Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Orna Therapeutics?
Orna Therapeutics is an operating biotech company, not an investment firm. Business and R&D decisions are made by the executive team led by CSO Joe, COO Ciaran, CBO Brian, CTO Siva, and CMO Frank Neumann, with oversight from its venture backers including MPM BioImpact.
What distinguishes Orna’s circular RNA from linear mRNA?
Orna’s engineered circular RNA is more stable than linear mRNA and, when paired with the firm’s proprietary lipid nanoparticles, can reach tissues beyond the liver. This capability opens therapeutic windows in oncology, autoimmune disease, and genetic disorders that current linear-mRNA approaches cannot readily address.
Which diseases does Orna’s pipeline target?
The internal pipeline uses panCAR in vivo CAR technology for oncology and autoimmune diseases. A collaboration with Merck targets infectious-disease applications. The delivery platform also shows potential for genetic diseases such as sickle-cell disease and beta-thalassemia by delivering directly to bone marrow without harsh preconditioning regimens.
Does Orna Therapeutics participate in external partnerships?
Yes. Its most prominent partnership is with Merck, focused on developing oRNA-based vaccines and therapeutics for infectious diseases. The firm has not disclosed additional active external collaborations but continues to evaluate strategic business-development opportunities per the 2024 appointment of its Chief Business Officer.
How is Orna Therapeutics financed?
Orna operates as a venture-backed private company. Investment details are undisclosed, though Executive Partner and CMO Frank Neumann's dual role at MPM BioImpact signals at least one institutional venture capital backer. The 2024 acquisition of ReNAgade Therapeutics suggests access to capital for platform-expanding transactions.
Where is Orna’s manufacturing and delivery expertise coming from?
CTO Siva previously led manufacturing at Alnylam and contributed to the launch of Onpattro, Givlaari, and Oxlumo. The team also includes former Moderna delivery and operations leaders who helped build early internal capabilities in LNP formulation and scalable mRNA manufacturing.
Does Orna have philanthropic structures or a family-office arm?
No. Orna Therapeutics is a pure-play biotechnology company. It does not maintain any philanthropic foundation or family-office division, and no philanthropic separation structures are disclosed on its site or in available primary sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: